Petros Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
Petros Pharmaceuticals, Inc. carries a market capitalization of 155,801.00, placing it among publicly traded companies globally. Its enterprise value stands at -4.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 155,801.00 |
| Enterprise Value | -4.12M |
Share Statistics
Petros Pharmaceuticals, Inc. currently has 42.37M shares outstanding.
| Shares Outstanding | 42.37M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Petros Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 0.10.
| PE Ratio | 0.10 |
| PS Ratio | N/A |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.13 |
| P/FCF Ratio | -0.04 |
| P/OCF Ratio | -0.04 |
Enterprise Valuation
| EV / Sales | 26.61 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Petros Pharmaceuticals, Inc. maintains a current ratio of 1.68, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.68 |
| Quick Ratio | 1.66 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 28.97 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Petros Pharmaceuticals, Inc.'s stock has declined approximately -84.375% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | -84.375% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -4.21M, while operating income came in at -4.21M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -4.21M |
| Pretax Income | -4.29M |
| Net Income | 3.19M |
| EBITDA | -4.21M |
| EBIT | -4.21M |
| Earnings Per Share (EPS) | -0.11 |
Balance Sheet
Total book value stands at -112.28M, with working capital of 1.77M providing operational flexibility.
| Cash & Cash Equivalents | 4.35M |
| Total Debt | N/A |
| Net Debt | -4.35M |
| Equity (Book Value) | -112.28M |
| Book Value Per Share | -2.94 |
| Working Capital | 1.77M |
Cash Flow
Petros Pharmaceuticals, Inc. produced -5.86M in operating cash flow over the past twelve months.
| Operating Cash Flow | -5.86M |
| Capital Expenditures | N/A |
| Free Cash Flow | -5.86M |
| FCF Per Share | -0.15 |
Dividends & Yields
The company's payout ratio of 17.85 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 17.85 |
| Shareholder Yield | 238.38 |
| FCF Yield | -2,560.04 |
Stock Splits
Petros Pharmaceuticals, Inc.'s most recent stock split took place on May 1, 2025 with a 25:1 split ratio.
| Last Split Date | 5/1/2025 |
| Split Ratio | 25:1 |
Scores
Petros Pharmaceuticals, Inc. posts an Altman Z-Score of -38.40, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -38.40 |